At Ochsner, we are committed to bringing clinical trials and new therapies to our community. We are seeking healthy adult volunteers who want to help us in the fight against COVID-19.
Ochsner Health will be a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase 3 clinical research study, ENSEMBLE trial, to evaluate the efficacy and safety of the Janssen’s investigational COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S.
This trial will collectively enroll up to 60,000 participants from all over the world. Over the next eight to 12 weeks, Ochsner will launch several clinical investigational sites across Louisiana, beginning with Ochsner Medical Center - Kenner and expanding to Ochsner Baptist and Ochsner Medical Complex - The Grove.
Led by Ochsner Principal Investigator Dr. Julia Garcia-Diaz, the Janssen study will enroll a limited number of randomized participants from across Louisiana, including those who have expressed previous interest in COVID-19 research.
If you or someone you know are interested in participating in COVID-19 research opportunities at Ochsner, please email COVIDVaccine@ochsner.org.
The purpose of this clinical research study is to determine the safety and efficacy (whether it works) of an investigational vaccine for the prevention of COVID-19.
You may be able to participate in this study if you:
Additional eligibility criteria will be assessed by the study doctor or staff. If you take part in this study, you will be in the study for up to 2 years and 1 month. Qualified participants will receive study-related medical care and the investigational vaccine or placebo at no cost. Qualified participants will also be reimbursed for reasonable trial-related travel expenses to and from study visits. The study will not pay for other medical care or current medication(s) needed to support your daily healthcare routine.
For more information about this clinical research study, contact us at COVIDvaccine@ochsner.org or 504-703-8283.
To learn more about Ochsner’s additional COVID-19 resources, please visit ochsner.org/coronavirus.
Janssen has joined other pharmaceutical companies in making a pledge to the world that it will continue to adhere to its high scientific, ethical and regulatory standards and will rely on robust clinical evidence to guide the development of its investigational COVID-19 vaccine candidate. Janssen is committed to transparency and sharing information related to the Phase 3 ENSEMBLE study – including the study protocol.
ENSEMBLE is being initiated in collaboration with the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Other Transaction Agreement HHSO100201700018C.
For more information and frequently asked questions about this clinical research study, visit www.ensemblestudy.com.